Adicet Bio Appoints Chief Medical Officer

Adicet Bio announced it has appointed Jesse McGreivy, M.D. as its Chief Medical Officer. Dr. McGreivy brings industry experience in successful development of novel cancer therapeutics.

"Jesse's vast experience and track record in progressing novel oncology drugs to approval will be instrumental to advancing the broad product pipeline derived from our universal immune cell therapy platform," said Aya Jakobovits, Ph.D., Founder, President and Chief Executive Officer of Adicet. "We are very pleased to welcome him to the Adicet executive team."

Prior to joining Adicet, Dr. McGreivy was the Chief Medical Officer at Acerta Pharma where he led the clinical development of acalabrutinib, a selective and potent BTK inhibitor currently in late stage clinical studies, until the company's acquisition by AstraZeneca for up to $7.0 billion. Before joining Acerta, Dr. McGreivy was the Chief Medical Officer at Pharmacyclics, Inc., where he oversaw the clinical development of ibrutinib (IMBRUVICA) and its successful U.S. and global filings. Previously, Dr. McGreivy served as a Medical Director at Amgen overseeing multiple late stage clinical studies in solid tumors with both small molecule and antibody therapies. Prior to Amgen, Dr. McGreivy was a Medical Director at Hoffmann-La Roche. He received his medical degree from The Ohio State University and completed his internship and residency in internal medicine, and his fellowship in hematology/oncology at Georgetown University.